Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids

Patent metadata

Field	Value
Publication number	US-9890361-B2
Application number	US-201314374404-A
Country	US
Kind code	B2
Filing date	Jan 25, 2013
Priority date	Jan 26, 2012
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

First claim

The invention claimed is:

1. A method of enhancing the infectivity of a human immunodeficiency virus, the method comprising contacting a cell infected with the human immunodeficiency virus with an alkyne-modified fatty acid or physiologically acceptable salt thereof in an amount effective to label the human immunodeficiency virus with the alkyne-modified fatty acid or physiologically acceptable salt thereof and thereby enhance the infectivity of the labeled human immunodeficiency virus, wherein the alkyne-modified fatty acid or physiologically acceptable salt thereof has the formula:
Y—CH 2 —X—CO 2 H

wherein,
Y is an ethynyl group; and
X is a linear carbon chain comprising 8 to 15 carbons; and wherein the alkyne-modified fatty acid is one that is attached directly or indirectly to a protein through an intracellular myristoylation or palmitoylation pathway.

2. The method of claim 1 , wherein the cell is a human cell or a non-human animal cell.

3. The method of claim 1 , wherein the human immunodeficiency virus is HIV-1.

4. The method of claim 1 , wherein the alkyne-modified fatty acid is 15-ethynylpentadecanoic acid, 12-ethynyldodecanoic acid, or physiologically acceptable salt thereof.

5. The method of claim 1 , wherein the alkyne-modified fatty acid is

or physiologically acceptable salt thereof.

6. The method of claim 1 , wherein the contacting is performed in a solution comprising at least one of animal serum, amino acids, buffers, fatty acids, glucose, hormones, inorganic salts, lipids, metal ion chelators, peptides, surfactants, trace metals, and vitamins.

7. The method of claim 1 , wherein the alkyne-modified fatty acid is one that is attached directly or indirectly to a protein through an intracellular myristoylation pathway.

8. The method of claim 1 , wherein the alkyne-modified fatty acid is one that is attached directly or indirectly to a protein through an intracellular palmitoylation pathway.

9. The method of claim 4 , wherein the alkyne-modified fatty acid is 15-ethynylpentadecanoic acid or physiologically acceptable salt thereof.

Assignees

• Life Technologies Corp
• Univ Johns Hopkins

Inventors

• Agnew Brian
• Graham David

Classifications

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2740/16045

  Special targeting system for viral vectors · CPC title